Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche.

Clinica chimica acta; international journal of clinical chemistry·2026

Same author

Echoes in AI: Quantifying lack of plot diversity in LLM outputs.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Subsecond optically controlled domain switching in freestanding ferroelectric BaTiO<sub>3</sub> membrane.

Nature communications·2025

Same author

Depleting the Action of EZH2 through PI3K-mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer.

Molecular cancer therapeutics·2025

Same author

Clinico-etiological Profile and Metabolic Complications in Pediatric Early Onset Obesity - Experience from a Tertiary Care Centre in India.

Indian pediatrics·2025

Same author

Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2-Stained Clinical Specimens in Breast Cancer.

Archives of pathology & laboratory medicine·2024

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

Polyglandular autoimmune syndrome-type I.

Rajesh R Joshi¹, Sudha Rao, S S Prabhu

¹Department of Pediatrics, B.J.Wadia Hospital for Children, Parel, Mumbai 400 012. rrj23@rediffmail.com

Indian Pediatrics

|January 5, 2007

Summary

Polyglandular autoimmune syndrome type I (PAS I) is a rare condition. This case report details a young boy with PAS I presenting with mucocutaneous candidiasis, hypoparathyroidism, and ectodermal dystrophy.

Area of Science:

Endocrinology
Immunology
Genetics

Background:

Polyglandular autoimmune syndrome type I (PAS I) is a rare autoimmune disorder.
PAS I is characterized by the triad of mucocutaneous candidiasis (MC), hypoparathyroidism (HP), and primary adrenal insufficiency.
Components of PAS I can manifest at various ages, necessitating ongoing patient monitoring.

Observation:

A six-and-a-half-year-old boy presented with symptoms indicative of PAS I.
The patient exhibited mucocutaneous candidiasis (MC) and hypoparathyroidism (HP).
Additionally, the boy presented with ectodermal dystrophy, a less common manifestation.

Findings:

This case highlights a pediatric presentation of Polyglandular autoimmune syndrome type I.
The patient's clinical features included mucocutaneous candidiasis, hypoparathyroidism, and ectodermal dystrophy.

More Related Videos

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Electrochemiluminescence Assays for Human Islet Autoantibodies

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Related Experiment Videos

Last Updated: Jul 17, 2026

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Electrochemiluminescence Assays for Human Islet Autoantibodies

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

The early onset and combination of these symptoms in a child underscore the syndrome's variability.

Implications:

Early diagnosis and comprehensive management are crucial for patients with PAS I.
Recognizing ectodermal dystrophy as a potential feature can aid in earlier diagnosis.
Further research into the genetic and immunological underpinnings of PAS I is warranted.